Typicality: | 0.421 |
Saliency: | 0.402 |
including avelumab | 3 | other |
antibody → target → pd-l1 | 13 |
antibody → bind to → pd-l1 | 4 |
antibody → target → human pd-l1 | 4 |
antibody → target → the pd-1/pd-l1 axis | 3 |
negative | neutral | positive |
0.081 | 0.517 | 0.401 |
Raw frequency | 24 |
Normalized frequency | 0.402 |
Modifier score | 0.500 |
Perplexity | 93.480 |